We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




AI-Enabled Technology Offers Future Heart Attack Risk Assessment

By HospiMedica International staff writers
Posted on 06 Mar 2024
Print article
Image: The Cleerly staging system for coronary artery disease has received FDA breakthrough device designation (Photo courtesy of Cleerly)
Image: The Cleerly staging system for coronary artery disease has received FDA breakthrough device designation (Photo courtesy of Cleerly)

When doctors diagnose cancer, they typically offer a prognosis and treatment plan based on a staging system that assesses the extent and location of the cancer in the body. Similarly, staging systems exist for common chronic diseases like hypertension, type 1 and type 2 diabetes, and asthma, which depend on various factors that indicate the disease's progression. However, heart disease lacks a clinically relevant staging system for atherosclerosis, a condition that impacts millions worldwide. Now, a new four-stage system has been introduced to measure the progression of coronary artery disease (CAD) by focusing on atherosclerotic plaque which determines future heart attack risk, rather than on secondary symptoms of heart disease.

Historically, the medical approach to heart disease has revolved around surrogates (such as cholesterol), symptoms (like chest pain or breathlessness), or disease consequences (such as ischemia or stenosis). Yet, many coronary lesions causing heart attacks are not linked to these factors, often presenting silently and without causing ischemia or stenosis. Cleerly’s (Denver, CO, USA; www.cleerlyhealth.com) CAD Staging System is an innovative noninvasive imaging-based software tool designed to analyze crucial aspects of coronary atherosclerosis, stenosis, and ischemia. This system aims to provide physicians with a more precise and individualized risk assessment for patients susceptible to major adverse cardiovascular events (MACE), including heart attacks before they occur.

Cleerly’s AI-powered digital care pathway identifies and quantifies atherosclerotic plaque in arteries, revealing not just the quantity but also the type and amount of plaque. The nature of the plaque is a crucial predictor of future heart attack risk and a key indicator of a patient's impending cardiac event. Cleerly transcends traditional heart disease metrics by analyzing, characterizing, and quantifying plaque types, enabling a more accurate assessment of a patient’s heart attack risk. Cleerly’s comprehensive reports offer healthcare professionals a detailed understanding of patient risk, encompassing everything from vessel-specific details and thorough plaque analysis to stenosis scoring. This empowers physicians to convert clinical data into tailored treatment plans for each patient, regardless of the patient’s position in the heart disease spectrum and potentially saving more lives. Cleerly has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its CAD Staging System.

“As Cleerly continues to develop cardiovascular innovations to support patients and healthcare professionals, we are honored to have received Breakthrough Device Designation and join the TAP Pilot,” said James K. Min, MD, Founder and CEO of Cleerly. “This designation from the FDA highlights the critical need for better heart disease risk assessment methods. Our approach to heart disease, inspired by the most successful preventive care paradigms in medicine – including mammograms, colonoscopies, and lung CTs – enables personalized diagnosis and risk assessment and exemplifies our commitment to enhancing CAD evaluation, aiming to prevent heart attacks before they occur.”

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Color Doppler Ultrasound System
KC20

Print article

Channels

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.